IXALTIS is a start-up pharmaceutical company specializing in genitourinary and renal diseases. The company was created by a team of experts, including scientists specialized in urology, pharmaceutical experts, and experienced managers. They have acquired the rights to three molecules from Sanofi, including their lead compound Litoxetine (IXA-001), and have completed a round of financing.

IXALTIS aims to develop treatments for genitourinary tract diseases with a high unmet medical need. They focus on identifying drugs that have already reached the clinical stage and re-exploring them for use in genitourinary tract disorders. Their leading compound, Litoxetine, has shown strong scientific rationale and promising preclinical and clinical data.

In addition to Litoxetine, IXALTIS also has two other compounds with the potential for development in related indications. Their mission is to become a leading developer of innovative pharmaceutical products for treating urogenital disorders, providing solutions for diseases that currently have limited or no satisfactory treatments. IXALTIS is a member of Lyonbiopôle, a Bio Cluster that serves as the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.

To learn more about IXALTIS and their products, you can visit their website or contact them directly